**MISOPROSTOL**

This document should be read in conjunction with this [DISCLAIMER](#).

**Formulary: Restricted**

<table>
<thead>
<tr>
<th>Class</th>
<th>Prostaglandin E₁ Analogue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation</td>
<td>Tablet: 200microg</td>
</tr>
<tr>
<td>Storage</td>
<td>Store below 25°C in the original packaging</td>
</tr>
</tbody>
</table>

**Dose and Administration**

- **Medical Management of 1<sup>st</sup> and 2<sup>nd</sup> Trimester Miscarriage**
  - Administered orally, sublingually or vaginally.
  - Refer to: [Use of Misoprostol](#)
  - Refer to: [Medical Management of Miscarriage](#)
- **Gestational Trophoblastic Disease (Molar Pregnancy)**
  - Used to ripen the cervix prior to D&C
  - Refer to: [Pregnancy Care: First Trimester Complications](#)

**Preoperative Administration**

PV 400microg, 1 hour prior to surgery to decrease blood loss

- Refer to: [Gynaecology (Non-oncological)](#)

**Pregnancy**

- **1<sup>st</sup> Trimester:** Contraindicated
- **2<sup>nd</sup> Trimester:** Contraindicated
- **3<sup>rd</sup> Trimester:** Contraindicated

**Breastfeeding**

- Considered safe to use

**Monitoring**

- **Sublingual administration:** monitor for oral irritation
- **Cardiovascular disease:** monitor cardiovascular status as prostaglandins may cause transient BP changes
- **Asthma or COPD:** may cause bronchospasm
- **Hepatic impairment:** avoid use in severe hepatic impairment

**Clinical Guidelines and Policies**

- KEMH Clinical Practice Guidelines:
  - Community Midwifery Program: [Primary Postpartum Haemorrhage at Home](#)
### Obstetrics & Gynaecology (Restricted): Use of Misoprostol

Gynaecology (Restricted): Medical Management of Miscarriage

Obstetrics & Gynaecology: Pregnancy Care: First Trimester Complications

Obstetrics & Gynaecology: Gynaecology (Non-oncological)

**KEMH Pharmaceutical & Medicines Management Guidelines:**

KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration

### References


---

**Keywords:** Misoprostol, miscarriage, post-partum haemorrhage, termination, prostaglandin

**Publishing:** ☑ Intranet ☑ Internet

**Document owner:** Chief Pharmacist

**Author / Reviewer:** KEMH Pharmacy Department

**Date first issued:** August 2015

**Version:** 4.0

**Last reviewed:** April 2020

**Next review date:** Apr 2023

**Endorsed by:** Medicines and Therapeutics Committee

**Date:** Jan 2018

**Standards Applicable:** NSQHS Standards: 1 Governance, 4 Medication Safety

---

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020